A trial in trained sprinters
Each participant completed three experimental sessions: placebo, caffeine at 3 mg/kg and caffeine at 6 mg/kg. The order was randomized and double-blind, with at least seven days between sessions. This design allows each sprinter to be compared with himself.
Sixty minutes after taking the dose, participants performed two maximal 60-meter sprints, followed by jump tests and a ten-second Wingate power test. The researchers also assessed start reaction time, force production in the starting blocks, stride characteristics and perceived exertion. These doses and this timing describe the experiment, not a recommendation for use.
Faster times, with variable additional gains
Compared with placebo, the 3 mg/kg dose reduced cumulative times at 10, 30 and 60 meters by 0.056, 0.083 and 0.123 seconds, respectively. With 6 mg/kg, the reductions reached 0.075, 0.115 and 0.175 seconds, respectively.
The higher dose therefore provided an additional gain of 0.032 seconds at 30 meters and 0.052 seconds at 60 meters compared with 3 mg/kg. At 10 meters, the additional difference of 0.019 seconds was not statistically significant in the main analysis. These group averages do not predict the gain for each athlete.
A higher dose did not perform better across the board
Both doses improved measures including reaction time, jump height and Wingate power compared with placebo. The 6 mg/kg dose provided additional benefits for jump height and the rate of force development in the starting blocks.
However, it did not further improve reaction time, perceived exertion, or mean and peak Wingate power. Stride length and frequency remained unchanged. The value of the higher dose therefore depends on the outcome measured.
What this trial cannot establish
The study involved a small, exclusively male sample and examined acute effects. Its results cannot be directly extended to women, beginners, repeated use or performance over a full 100 meters.
The dossier provides access only to the PubMed abstract, not the full text. It does not provide confidence intervals or tolerability results. Funding and conflicts of interest have not been verified. Without this information, faster times alone are not enough to establish the best balance between performance and adverse effects.
Limitations to keep in mind
Small male sample, acute effects and sprints limited to 60 meters. Only the PubMed abstract was consulted. Confidence intervals and tolerability data were not provided in the dossier; funding and conflicts of interest were not verified.
What we can take away
In this trial, caffeine improved several measures of sprint performance. The higher dose reduced 60-meter times further, without providing an across-the-board advantage on all tests or establishing an optimal dose to use.
Sources and provenance
- Acute doses of 3 and 6 mg/kg caffeine produce outcome- and phase-specific improvements in male 100-m sprinters: A randomized, double-blind, placebo-controlled crossover trial.
Source date: 2026-11-10.
Journal Article, Randomized Controlled Trial · Résumé PubMed uniquement, texte intégral non consulté


